Comparative Pharmacology
Head-to-head clinical analysis: DYCLONE versus ZTLIDO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DYCLONE versus ZTLIDO.
DYCLONE vs ZTLIDO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking impulse initiation and conduction.
ZTLIDO (lidocaine) is a sodium channel blocker that binds to voltage-gated sodium channels in neuronal membranes, stabilizing the membrane and inhibiting the initiation and conduction of nerve impulses, thereby producing local anesthesia.
0.5% to 1% solution: 2 mL (10 mg) applied topically to the affected area q4h prn; may be used as a rinse or spray.
1.8% lidocaine topical patch: Apply up to 3 patches at once to intact skin for up to 12 hours in a 24-hour period.
None Documented
None Documented
Approximately 2-4 hours; clinical context: rapid clearance limits systemic accumulation with topical use.
Terminal elimination half-life is 1.5 to 2.0 hours in patients with normal renal function; prolonged in renal impairment (up to 6-8 hours with CrCl <30 mL/min).
Renal: <5% unchanged; Biliary/fecal: negligible; primarily metabolized in liver, metabolites excreted renally.
Primarily renal excretion as unchanged drug (80-85%) and metabolites (10-15%); less than 5% excreted in feces.
Category C
Category C
Topical Anesthetic
Topical Anesthetic